Portfolio
Innovative Oncology therapies across multiple drug classes to improve patient lives
Portfolio
Innovative Oncology therapies across multiple drug classes to improve patient lives
Candidate Name
Class
Indication
EP0062/vosilasarm is an orally available non-steroidal SARM currently being investigated in an adaptive phase 1/2 dose optimisation study in patients with advanced ER+/AR+ breast cancer. Data from an initial phase 1 trial showed encouraging responses with an acceptable safety and tolerability profile in heavily pre-treated AR+/ER+/HER2- advanced breast cancer patients.
Candidate Name
Class
Indication
Candidate name
EP0031
Class
Selective RET Inhibitor
Indication
RET+ Solid Tumours
EP0031 is a next generation selective RET inhibitor currently being investigated in a modular interventional phase 1/2 study in adult patients with advanced RET-altered malignancies.
Latest:
Candidate Name
Class
Indication
A novel first-in-class B7H3 antibody drug conjugate (ADC) with eribulin as a payload, currently being investigated in a Phase 1 trial in China. B7H3 is a clinically validated target expressed across a wide range of cancer types. Eribulin is an established chemotherapy agent.
Latest:
Candidate Name
Class
Indication
A first-in-class next-generation immunotherapy agent targeting CNTN4, a recently discovered checkpoint protein that is highly expressed in a wide range of tumour types.
CNTN4 regulates T-cell activity negatively through binding with APP; the target is overexpressed in multiple tumour types e.g. gastric, prostate, liver, melanoma, and bladder.
*Phase 1 ready with regulatory approval in two counties.
Latest: